logous progenitor cells from the bone marrow or peripheral blood, nephrotoxicity is one of the most frequent and often dose-limiting toxicities from this treatment. 2,4,5 Yet, the High-dose carboplatin, etoposide and ifosfamide (CEI) is an active chemotherapy regimen (HDCT) in solid incidence of this side-effect varied considerably in a large number of trials and the implications on hematologic recovtumors and lymphomas. In patients with previous exposure to cisplatin, its nephrotoxicity is dose-limiting.
Treatment
The high-dose combination of carboplatin, etoposide and
The details of the dose escalation and supportive care have ifosfamide (CEI) represents an active and potentially curabeen previously reported. 5 Carboplatin and etoposide were tive chemotherapy regimen (HDCT) in a number of solid administered as a short infusion over 1 h in divided doses tumors and lymphomas.
1-6 Whereas substantial hematolover 3 and 4 days, respectively. Ifosfamide was given as a ogic toxicity can be fully reversed by the reinfusion of autocontinuous infusion over 22 h in divided doses for 4 days. Mesna and vigorous hydration were used for uroprotection in all patients. No a priori adjustments in the carboplatin boplatin and etoposide on day 0. In 69 patients bone marrow, in 75 PBPC, and in six patients bone marrow as Age (years) well as PBPC were used as stem cell rescue (Table 3) day +1 until recovery of leukocyte counts у1000/l for 3 (Ϯ mediastinum) mediastinum 3 (7) 5 (5) consecutive days. between 9 and 10 g/l and platelets Ͼ20/nl. Blood products Serum creatinine prior HDCT were irradiated with 25 Gy before transfusion.
(in mg/ml) median 0.9 0.9 range 0.5-1.7 0.5-1.4
Clinical monitoring and follow-up
Body weight prior HDCT (in kg) median 72 76
All patients with germ cell tumors who were treated in con- and immediately prior to HDCT that included a detailed physical examination, the tumor markers alphafetoprotein a All differences were not statistically significant with P Ͼ 0.05.
and human choriogonadotrophin, a full blood count and an extensive blood chemistry profile including infectious disease markers as well as detailed radiographic studies. Roupatients, and a combination of both in an additional six (4%) patients. As CEI was initially evaluated in a phase tine monitoring during HDCT consisted of a daily clinical evaluation, daily blood counts and a daily blood chemistry I/II trial, planned doses ranged in the first 74 patients for carboplatin from 1500-2000 mg/m 2 , for etoposide from profile. Follow-up evaluations were performed at 6 and 12 weeks post-HDCT and consisted of a detailed physical 1200-2400 mg/m 2 , and for ifosfamide from 0-10 g/m 2 (Table 2) . Once the maximal tolerated dose was determined examination, a standard chemistry profile in addition to tumor markers and radiographic studies. Additional investiat carboplatin 1500 mg/m 2 , etoposide 2400 mg/m 2 , and ifosfamide 10 g/m 2 , all subsequent patients were scheduled gations were performed as clinically indicated. Thereafter patients were re-evaluated every 3 months during the first to receive this combination at a fixed dose. However, in 11 patients who had pre-existing renal impairment or who had year and every 6 months during subsequent years. experienced reversible nephrotoxicity during conventionaldose cisplatin treatment, only a cycle of carboplatin 1500
Definitions of nephrotoxicity and other non-hematologic mg/m 2 and etoposide 2400 mg/m 2 without additional ifosfatoxicities mide was given (Table 2 ). In addition, in patients who showed evidence of deteriorating renal function as defined Serum creatinine determinations were performed in the hospital routine laboratory on a commercially available Technby a rise in the serum creatinine Ͼ0.5 mg/dl over the indi- 
Patients with Patients
Patients who had developed acute nephrotoxicity, but nephrotoxicity without died from treatment-related causes were excluded from
further analyses of hematologic recovery or non-hematol-
ogical toxicities, supportive care requirements and hospital stay. 
Renal toxicity and patient characteristics
Of all 150 patients, 43 (29%) developed acute nephrotoxicicon DAX 72 analyser (Technicon-Bayer, Mü nchen, Germany) according to the manufacturer's instructions with ity including 12 (8%) patients who required hemodialysis. The remaining 107 patients either had no measurable an upper normal range of 1.3 mg/dl for adults. In each patient the creatinine clearance (CC CL ) was calculated decline in their renal function or suffered a decline that did not meet the criteria for acute nephrotoxicity used in the according to the Cockroft formula at baseline before HDCT, at the time of the maximal serum creatinine deterpresent analysis. In three patients who required hemodialysis, nephrotoxicity occurred in the context of severe cenmination after HDCT, and at discharge. 7 Nephrotoxicity was defined either as a decline in the calculated creatinine tral nervous toxicity and multiorgan failure and all died. Two other patients died from pneumonia and developed clearance of 50% or more below the baseline value or as an absolute increase of 1 mg/dl or more irrespective of the multiorgan failure as a preterminal event. The remaining seven patients suffered renal impairment as single organ time of onset of nephrotoxicity or potential contributing failure; two of them continued to require hemodialysis after discharge.
As shown in Figure 1 , the 43 patients with acute nephrotoxicity had a CC CL at a median of 38 ml/min (range 9-81 ml/min) after HDCT corresponding to a maximal serum creatinine at a median of 3.2 mg/dl (range 1.1-12.4 mg/dl). The 107 patients without acute nephrotoxicity had a minimal CC CL at a median of 89 ml/min (range 46-160 ml/min) after HDCT corresponding to a maximal serum creatinine at a median of 1.3 mg/dl (range 0.7-2.3 mg/dl). The majority of patients who suffered from acute nephrotoxicity did so within a few days after the initiation of HDCT (Figure 2) . However, three patients experienced nephrotoxicity late at 15, 21 and 30 days after HDCT was started; all three in the context of empiric intravenous amphotericin B administration.
At the time of discharge, all but two of the 43 patients values with a median of 1.3 mg/dl (range 0.5-6.0 mg/dl) at the time of discharge as compared to patients without acute nephrotoxicity (median 0.9 mg/dl, range 0.5-1.4
(range 0.9-2.9 mg/dl) and one patient still requires hemodialysis more than 5 years after HDCT. This compares to a mg/dl; P Ͻ 0.001). This difference in renal function between the two groups persisted with longer follow-up of median serum creatinine of 0.9 mg/dl (range 0.7-1.7 mg/dl) and no patient on hemodialysis in long-term survivors withpatients (median 50 months, range 17-88 months). In longterm survivors who had experienced acute nephrotoxicity out acute nephrotoxicity after HDCT (P = 0.001). Patients with and without acute nephrotoxicity did not differ in their after HDCT the median serum creatinine was 1.3 mg/dl treatment characteristics before HDCT. In particular, neither the number of prior treatment regimens nor the extent of prior cisplatin exposure, nor the baseline renal function as determined by serum creatinine values and the CC CL could be used as reliable predictors for acute nephrotoxicity after HDCT (Table 1) . However, acute nephrotoxicity occurred significantly more often in 13/19 (63%) patients treated at dose levels 6 and 7 with doses of carboplatin Ͼ1500 mg/m 2 as compared to 30/131 (23%) patients treated at the other dose levels with a carboplatin dose of 1500 mg/m 2 (P Ͻ 0.001) ( Table 2) .
High-dose treatment
The first 74 patients were treated in a phase I/II trial with stepwise escalation of all three drugs contained in the CEI regimen. Thereafter a fixed combination of CEI was used (Table 2 ). In 14 and 21% of patients with nephrotoxicity an increase in the serum creatinine of 0.5 mg/dl or more over the baseline value occurred early enough during HDCT to reduce the doses for etoposide and ifosfamide according to the study protocol (Table 3) . Dose reductions were less frequent for etoposide in 3% (P Ͻ 0.05) and for ifosfamide in 11% of patients (P = 0.14) without nephrotoxicity. Changes in the supportive care after HDCT during the study period are reflected in the data set and were determined by the availability of hematopoietic growth factors and stem cell technology at the time. As higher doses of carboplatin were used in the earlier studies BM was more often use of a growth factor in patients with or without nephro-toxicity were found (Table 3) . Of the patients treated with differences were found for WHO grade 3 or 4 liver toxicity (32 vs 9%, P Ͻ 0.05), grade 2 or more cutaneous toxicity higher doses of carboplatin at dose levels 6 and 7 who had the highest incidence of acute nephrotoxicity 16/19 (84%) (50 vs 17%, P Ͻ 0.001), grade 2 or more central nervous toxicity (30 vs 7%, P Ͻ 0.001), grade 2 or more peripheral had a bone marrow graft as compared to 53/131 (41%) patients treated at the other dose levels (P Ͻ 0.001). Siminervous toxicity (58 vs 22%, P Ͻ 0.001), and grade 2 or more ototoxicity and tinnitus (53 vs 24%, P Ͻ 0.05). larly, only 10/19 (53%) patients treated at dose levels 6 and 7 received growth factors as compared to 115/131 (88%) of the other patients (P Ͻ 0.001).
Treatment response In 11 patients who had experienced transient nephrotoxicity during previous conventional-dose salvage treatments, Five patients (3%) died from treatment-related toxicities shortly after HDCT and 84 (49%) patients died from disifosfamide was omitted from the high-dose combination. This resulted in an uneventful clinical course after HDCT ease progression after a median of 8 months (range 1-53 months). One patient is lost to follow-up. 60 (40%) patients with only 3/11 (27%) developing acute nephrotoxicity after HDCT (Table 2) .
are alive with a median follow-up of 50 months (range 17-88 months). Neither the rate of complete or marker-negative partial remissions in 21/43 (49%) patients nor the rate Hematologic recovery, supportive care and nonof durable responses in 18/43 (42%) patients with acute hematologic toxicities nephrotoxicity differed from patients without acute nephrotoxicity in whom 61/107 (57%) remissions, and 31/107 In univariate analysis, the times to recovery of leukocytes Ͼ1000/l, of neutrophils Ͼ500/l, and of unsubstituted (29%) durable responses were observed (P Ͼ 0.05 for both comparisons). Similarly, despite more early deaths in platelets Ͼ20 000/l were found to be significantly delayed in patients who experienced acute nephrotoxicity as compatients with acute nephrotoxicity as compared to patients without this complication, there was no difference in the pared to patients without acute nephrotoxicity (Table 4) . However, when examined by multivariate analysis, an projected overall survival rates at 2 years or later (Figure 3) . influence of the occurrence of nephrotoxicity on hematologic recovery could no longer be demonstrated (Table 5) . On the other hand, the use of peripheral blood progenitor Discussion cells significantly shortened the time to recovery of leukocytes and neutrophils, as well as of platelets. Similarly, Renal dysfunction is a common and often dose-limiting side-effect of HDCT. In particular, the use of high-dose administration of G-CSF or GM-CSF related to a significantly faster recovery of leukocytes and neutrophils, but carboplatin and ifosfamide has been associated with this form of toxicity. 2,4,5,11-14 Patients with prior exposure to had no influence on platelet recovery. Non-hematologic toxicities were more frequent in patients who had experinephrotoxic agents such as cisplatin or with pre-existing renal impairment may be at a higher risk. 15, 16 Yet, the incienced acute nephrotoxicity as compared to patients who did not suffer from this complication. Whereas no differences dence and clinical implications of renal dysfunction after HDCT are unclear. In clinical reports about the use of CEI were found for nausea, mucositis or diarrhea, significant in germ cell tumors, nephrotoxicity has been reported to be completely absent or represented an intolerable and dose- In the present analysis, nephrotoxicity after CEI was defined as either a decline of 50% or more below the base- that might help to predict acute nephrotoxicity after CEI (No.) treatment in the present analysis. 15, 16 The number of cispla- and ifosfamide resulted in a significantly higher incidence 818 Patients who experienced acute nephrotoxicity also had more other non-hematologic toxicities such as central and peripheral nervous toxicity, hearing impairment, liver toxicity, and cutaneous toxicity. In fact, three patients died in the context of multiorgan failure that was probably precipitated by renal dysfunction. We anticipated that acute nephrotoxicity would also lead to impaired hematologic recovery mediated by bone marrow stromal damage, excess drug levels, delayed excretion of cytotoxic drugs or persistence of cytotoxic metabolites at the time of stem cell reinfusion. In univariate analysis, the time to platelet recovery factor after HDCT or rescue with PBPC, proved to be more important for early hematologic recovery than the occurrence of nephrotoxicity. In particular, PBPC were a strong of acute nephrotoxicity. Two previous reports that studied independent predictor for early trilineage reconstitution. HDCT with CEI in more heterogenous patient populations Finally, treatment outcome as reflected by the rate of favdescribed the frequency of acute nephrotoxicity as 46 and orable responses and overall survival did not differ in 29%, respectively. 2, 4 In both studies the decline of renal patients with or without acute nephrotoxicity after HDCT. function also occurred early after HDCT and in both studies Although all patients who died also had significant renal no risk factors for acute nephrotoxicity after HDCT with impairment, the overall mortality rate of 3% was low as CEI were found. In the future, monitoring for more sensicompared to other reports using HDCT in a similar patient tive markers of subclinical renal damage might be required population. In conclusion, CEI is an active regimen in germ even before HDCT is initiated.
cell tumors with substantial and unpredictable, albeit Empiric dose reductions of CEI have been suggested as manageable nephrotoxicity. soon as a deterioration of renal function becomes apparent in order to prevent further, and potentially irreversible, renal damage.
2,4 An increase to a maximum serum creatinine of 1.5 mg/dl or more with an absolute increase of 0.5 References mg/dl or more over the baseline value was chosen as a cutoff level to stop chemotherapy administration in one trial. according to a patients' renal function has been suggested
